Shares of Minerva Neurosciences (NERV) - Get Report rose 10.3% to $9.10 in premarket trading on Thursday. The Waltham, Mass.-based firm after the market close on Wednesday said it has amended its  co-development and license agreement with Johnson & Johnson's (JNJ) - Get Report Janssen Pharmaceutica NV regarding, insomnia drug and depression treatment candidate MIN-202 (JNJ 42827922). Minerva will also reacquire all of its shares owned by Johnson & Johnson's venture capital arm. MIN-202 (JNJ 42827922) is a selective orexin-2 receptor antagonist.

As part of the amended pact, Minerva will have global strategic control of the development of MIN-202 to treat insomnia, and Janssen will forego its right to royalties on MIN-202 insomnia sales in Minerva territories.

The amendment and stock repurchase are conditional upon the closing of Johnson & Johnson's pending purchase of Swiss biotech Actelion and approval by the European Commission.

Meanwhile,

XBiotech

(XBIT) - Get Report

shares were up 9.9% to $8.10. The Austin, Texas-based firm said

data

from its European phase three study of advanced colorectal cancer patients treated with Hutruo (MABp1) will be presented on June 3 at the American Society of Clinical Oncology meeting in Chicago.

Among the other biotech movers was Aduro Biotech (ADRO) - Get Report , up 4% to $10.40. The Berkeley, Calif.-based company said the U.S. Food and Drug Administration has cleared the investigational new drug application for ADU-S100 (also known as MIW815), a STING pathway activator, to be evaluated in tandem with Novartis' (NVS) - Get Report investigational anti-PD-1 checkpoint inhibitor PDR001 for the treatment of advanced/metastatic solid tumors or lymphomas. The phase 1b study is expected to be initiated in the second half of the year.

Jim Cramer and the AAP team give their analysis of Hewlett Packard Enterprise's (HPE) - Get Report fiscal-second-quarter results. Find out what they are telling their investment club members. Get a free trial subscription to Action Alerts PLUS.

Meanwhile, over on Real Money, Cramer says Ollie's Bargain Outlet Holdings (OLLI) - Get Report is "the play on the destruction of brick and mortar as we know it." Get his insights or analysis with a free trial subscription to Real Money.